Colorectal Cancer Clinical Trials
CPMC Cancer Services
Oncology / Cancer Clinical Trials Main Page | Adult Clinical Trials Main Page
Further protocol information can be found on the links below at ClinicalTrials.gov
Active Trials
Title: A Phase III, Prospective, Randomized, Trial Comparing Laparascopic-assisted vs. Open Resection for Rectal Cancer
Description: Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Stage IIA, Stage IIIA, or Stage IIIB Rectal Cancer
Investigators: CPMC Oncologists
Eligibility: Patients with rectal cancer which can be removed with surgical resection, and who have completed chemotherapy and/or radiation therapy
Status: Active and open to enrollment
Contact: Brenda Eng, 415-600-1775,
Email: EngB@cpmcri.org about Study ACOSOG-Z6051
Title: A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients With Resected Stage III Colon Cancer
Description: Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery
Investigators: CPMC Oncologists
Eligibility: Subjects with colon cancer without rectal cancer
Status: Active and open to enrollment
Contact: Chrissy Raymundo, 415-600-3613,
Email: RaymunCL@cpmcri.org about Study CALGB 80702
Title: A Phase II Study of Oxaliplatin, Capecitabine, Cetuximab and Radiation in Pre-Operative Therapy of Rectal Cancer
Description: This trial is studying the side effects and how well giving oxaliplatin, capecitabine, and cetuximab together with radiation therapy followed by surgery works in treating patients with stage II or stage III rectal cancer
Investigators: CPMC Oncologists
Eligibility: Stage II or III primary adenocarcinoma of the rectum
Status: Active and open to enrollment
Contact: Chrissy Raymundo, 415-600-3613,
Email: RaymunCL@cpmcri.org about Study SWOG-S0713
Title: Phase Ib Open-Label Dose-Escalation Study of the Safety and Pharmacokinetics of Multiple Doses of Dulanermin Administered IV in Combo With Camptosar®/Erbitux® Chemo or the Folfiri Regimen With or Without Bevacizumab in Subjects With Previously Treated Metastatic Colorectal Ca
Description: A Study of Dulanermin Administered in Combination With Camptosar®/Erbitux® Chemotherapy or FOLFIRI (With or Without Bevacizumab) in Subjects With Previously Treated Metastatic Colorectal Cancer
Investigator: Ari Baron, MD
Eligibility: Subjects must have histoligically or cytologically confirmed metastic colorectal cancer. Confirmation may be from primary tumor or metastasis
Status: Active but closed to enrollment
Contact: Anna Ruiz, 415-600-3214,
Email: RuizAC@cpmcri.org about Study APO3583g
Title: A Phase Ib Study of the Safety and Pharmacokinetics of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal Cancer
Description: A Study of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal Cancer
Investigator: Ari Baron, MD
Eligibility: Subjects must have histoligically or cytologically confirmed metastic colorectal cancer. Confirmation may be from primary tumor or metastasis
Status: Active but closed to enrollment
Contact: Anna Ruiz, 415-600-3214,
Email: RuizAC@cpmcri.org about Study APO4565g
- updated May 2011
Back to top